Compare SPPL & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPPL | CODX |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 15.6M |
| IPO Year | 2023 | 2017 |
| Metric | SPPL | CODX |
|---|---|---|
| Price | $4.21 | $0.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 3.5K | ★ 2.1M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,591,508.00 | $507,892.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $31.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.27 | N/A |
| 52 Week Low | $2.18 | $0.23 |
| 52 Week High | $16.80 | $1.55 |
| Indicator | SPPL | CODX |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 52.37 |
| Support Level | $3.49 | $0.34 |
| Resistance Level | $4.75 | $0.42 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 57.85 | 84.37 |
Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software. The majority of its revenue is generated from the Robots segment.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.